Overview
This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.
Description
Moxibustion plus cupping may be effective and safe for convalescent patients with COVID-19, but evidence is limited. The randomized clinical trial may help to provide evidence-based factors for improving the patients' symptoms in the convalescence of COVID-19.
Eligibility
Inclusion Criteria:
- Clinical diagnosis of the convalescence of COVID-19 (defined by the Chinese Guideline for COVID-19 in 2020 Trial Version 7).
- 18-70 years old;
- Cough / chest tightness / shortness of breath / asthenia after exercise, with at least 2 of the above symptoms and the average VAS score (last 48 hours) 40 points;
- Volunteers with informed consent;
- In the past 1 week, CT showed that there was still inflammation or pulmonary fibrosis in the lung, or the oxygen saturation95% without inhaling oxygen, or the walking distance of the six-minute-walking test 350 meters, with one of the above criteria;
Exclusion Criteria:
- Surgery in the lung that affects lung function;
- Rely on mechanical ventilation to maintain lung function;
- Chronic lung diseases affecting lung function;
- Diseases affecting heart function;
- Severe basic diseases;
- Resting heart rate > 120/min, systolic blood pressure > 180mmHg, diastolic blood pressure > 100mmHg;
- Unstable angina or myocardial infarction in the past 1 month;
- Severe obesity (BMI>30kg/m2);
- Allergic constitution;
- Pregnant or lactating women;
- Disabled patients;
- Mentally ill Patients;
- Participating in other clinical trials;
- Poor compliance or other complicate conditions according to the researchers.